AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-18 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
=== Other applications === Easton-Bell Sports, Inc. have been in partnership with Zyvex Performance Materials, using CNT technology in a number of their bicycle components – including flat and riser handlebars, cranks, forks, seatposts, stems and aero bars. Amroy Europe Oy manufactures Hybtonite carbon nano-epoxy resins where carbon nanotubes have been chemically activated to bond to epoxy, resulting in a composite material that is 20% to 30% stronger than other composite materials. It has been used for wind turbines, marine paints and a variety of sports gear such as skis, ice hockey sticks, baseball bats, hunting arrows, and surfboards. Surrey NanoSystems synthesizes carbon nanotubes to create vantablack ultra-absorptive black paint. "Gecko tape" (also called "nano tape") is often commercially sold as double-sided adhesive tape. It can be used to hang lightweight items such as pictures and decorative items on smooth walls without punching holes in the wall. The carbon nanotube arrays comprising the synthetic setae leave no residue after removal and can stay sticky in extreme temperatures. Tips for atomic force microscope probes. One proposed use of carbon nanotubes is in paper batteries, developed in 2007 by researchers at Rensselaer Polytechnic Institute. Another highly speculative proposed use in the field of space technologies is to produce high-tensile carbon cables required by a space elevator.
== Types == Enzymes vary in the specificity of the substrates that they bind to, in order to carry out specific physiological functions. Some enzymes may need to be less specific and therefore may bind to numerous substrates to catalyze a reaction. On the other hand, certain physiological functions require extreme specificity of the enzyme for a single specific substrate in order for a proper reaction and physiological phenotype to occur. The different types of categorizations differ based on their specificity for substrates. Most generally, they are divided into four groups: absolute, group, linkage, and stereochemical specificity.
=== Pharmaceuticals === The increasing sophistication of pharmaceutical materials has necessitated the use for more sensitive, thermodynamic based techniques for materials characterization. For these reasons, IGC, has seen increased use throughout the pharmaceutical industry. Applications include polymorph characterization, effect of processing steps like milling, and drug-carrier interactions for dry powder formulations. In other studies, IGC was used to relate surface energy and acid-base values with triboelectric charging and differentiate the crystalline and amorphous phases [23].
Sources: en.wikipedia.org
Nicotinamide riboside kinase 1 is an enzyme that in humans is encoded by the NMRK1 gene. As both a nicotinate riboside kinase (EC 2.7.1.173), and a ribosylnicotinamide kinase (EC 2.7.1.22), this enzyme helps perform a step in the process of converting certain forms of niacin/Vitamin B3 into active coenzymes like NAD+. In humans, nicotinamide riboside kinase 1 is expressed in most tissues of the body, compared to the other isozyme, nicotinamide riboside kinase 2, which is predominantly found in muscles.
During the later part of the 18th century, fundamental internal reforms were attempted in the Polish–Lithuanian Commonwealth as it slid into extinction. The reform activity, initially promoted by the magnate Czartoryski family faction known as the Familia, provoked a hostile reaction and military response from neighboring powers, but it did create conditions that fostered economic improvement. The most populous urban center, the capital city of Warsaw, replaced Danzig (Gdańsk) as the leading trade center, and the importance of the more prosperous urban social classes increased. The last decades of the independent Commonwealth's existence were characterized by aggressive reform movements and far-reaching progress in the areas of education, intellectual life, art and the evolution of the social and political system. The royal election of 1764 resulted in the elevation of Stanisław August Poniatowski, a refined and worldly aristocrat connected to the Czartoryski family, but hand-picked and imposed by Empress Catherine the Great of Russia, who expected him to be her obedient follower. Stanisław August ruled the Polish–Lithuanian state until its dissolution in 1795. The king spent his reign torn between his desire to implement reforms necessary to save the failing state and the perceived necessity of remaining in a subordinate relationship to his Russian sponsors. The Bar Confederation (1768–1772) was a rebellion of nobles directed against Russia's influence in general and Stanisław August, who was seen as its representative, in particular.
=== Buyout of Anderson, headquarters relocation, and expansion === In 1933, Anderson sold his half of the business to Ingram, and the following year the company moved its corporate headquarters to Columbus, Ohio. Co-founder Billy Ingram was followed as head of the firm by his son E. W. Ingram Jr. and grandson E. W. Ingram III. In 1959, White Castle expanded into new markets for the first time since the 1920s. Billy Ingram, who had retired to Miami in 1958, built three White Castle restaurants there. The company closed the Florida operations in 1967 due to inefficient supply distribution. Throughout its existence, White Castle has been a private company and relied on company-owned stores. It remains privately held today, and its restaurants are all company-owned; none are franchised, except very briefly in Japan during the 1980s and more recently in China since 2017.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.